Navigation Links
Candidate vaccine to reduce hepatitis C viral load.

Hepatitis C virus is the leading cause of death and liver transplant in the western world. This disease is also very common that it is incidence is five times more when compared to HIV/ AIDS. // Hence researchers at the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine candidate to treat hepatitis C infection.

This vaccine technique is very effective in the treatment of Hepatitis C (HCV) infection. It reduced the load of the carrier virus in the body of the mice tremendously in the order of 100000 times when compared to the control. The Canadian Institutes of Health Research (CIHR) and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) funded the research.

The researchers mainly made use of the dendritic cells to fight against the Hepatitis C virus. Dendritic cells play an important role in activation of the immune system. The vaccine significantly reduced the amount of viral protein in the body. This help us to later develop treatments which will pave way to help the patients suffering from liver disease caused by the virus.

People (20%) who have the disease remove the virus without any major problem. When the disease becomes chronic then the immune system finds it difficult to remove the viral load from the body. But studies reveal that in patients suffering from chronic hepatitis there is alteration in the function of the dendritic cells.

Hence these vaccines were created which could signal the dendritic cell and help in the proper activation of the immune system. Then the patient is in a position to control from the body.

The designing of a vaccine is very time consuming and troublesome because the virus always keeps mutating. A patient suffering from the disease may harbor with many different types of strains. Hence the VIDO came up with a vaccine that has a broad range of action and is effective against all strains.


'"/>




Page: 1

Related medicine news :

1. New Test Identifies Candidates For Cardiac Defibrillator
2. HIV-Positive Woman To Be Congress Candidate In Assam
3. Reservation For SC/ST Candidates Under 50% All India Quota
4. New hope for cancer victims – will vaccine cure the deadly bug
5. New vaccine helps allergy and asthma patients
6. Man against HIV – new vaccine ready for human trials
7. New vaccine helps allergy and asthma patients
8. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
9. HIV did not arise from polio vaccine
10. Double impact vaccine
11. High Demand for a child vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for ... 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device ... of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: